CytomX Therapeutics to Present at Upcoming September Investor Conferences

About this update from Cytomx Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Cantor Global Healthcare Conference 2025 Date: Thursday, September 4, 2025 Fireside Chat: 8:35 a.m. ET Location: New York, NY H.C. Wainwright 27 th Annual Global Investment Conference Date: Tuesday, September 9, 2025 Formal Presentation: 11:30 a.m. ET Location: New York, NY Morgan Stanley 23 rd Annual Global Healthcare Conference Date: Wednesday, September 10, 2025 Fireside Chat: 1:05 p.m. ET Location: New York, NY A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com . In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX Therapeutics, Inc. CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb , Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter). Company Contact: Chris Ogden SVP, Chief Financial Officer [email protected] Investor Contact: Precision AQ (formerly Stern Investor Relations) Stephanie Ascher [email protected] Media Contact: Redhouse Communications Teri Dahlman [email protected] Source: CytomX Therapeutics Inc.

View stock analysis, news, and events for Cytomx Therapeutics, Inc.